Compounds, compositions, methods, and uses for treating leptin resistance, obesity, diabetes mellitus and metabolic syndrome

a technology of leptin resistance and metabolic syndrome, applied in the field of chemical compounds, can solve the problems of insensitive exogenous leptin and high levels of circulating leptin in obese patients

Pending Publication Date: 2021-10-21
LINK THERAPEUTICS LLC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes different ways to improve the effectiveness of drugs that target specific areas of the body called leptins. These improvements can help reduce symptoms such as weight loss, type 2 diabetes, and insulin-related problems associated with these conditions.

Problems solved by technology

The technical problem addressed by this patent is how to develop a therapy for treating excessive accumulation of fat called leptin without causing any side effects like those caused by lack of leptin expression.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds, compositions, methods, and uses for treating leptin resistance, obesity, diabetes mellitus and metabolic syndrome
  • Compounds, compositions, methods, and uses for treating leptin resistance, obesity, diabetes mellitus and metabolic syndrome
  • Compounds, compositions, methods, and uses for treating leptin resistance, obesity, diabetes mellitus and metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

example

[0274]Hypothetical examples are disclosed below to illustrate the invention. Persons skilled in the art will recognize many different variations of these hypotheticals based on the disclosure in this document and known prior art. All variations are intended to be within the scope of this invention. Therefore, the examples disclosed are not intended to limit the scope of the claims. Animal Distribution into Treatment Groups: Mice were distributed into treatment groups by body weight so that there is no significant difference between the means across groups.

[0275]Intraperitoneal (IP) Dosing: A 27½″ gauge needle is used for injection. Injection volume for the study is 5 ml / kg per injection. Restrain the mouse and identify the injection location which is above or equal to the top of the hips and below the middle of the abdomen, generally just to the right of the midline.

[0276]Glucose Tolerance Test (ipGTT): Mice are weighed and transferred to individual clean cages that provide water and

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Digital informationaaaaaaaaaa
Volumeaaaaaaaaaa
Login to view more

Abstract

Novel leptin and leptin-fusion protein-small molecule drug conjugates are disclosed, where conjugation takes place through the use of cleavable and non-cleavable linkers. The small molecules chemically linked to the protein carrier are imported into the specific leptin-responsive target tissue or cell through receptor-mediated endocytosis and released from the carrier protein through enzymatic cleavage of the linker-drug moiety or through lysosomal degradation of the carrier protein. Free drug then act to modify leptin receptor-triggered biochemical pathways that are altered in conditions of leptin-resistance. Drug will correct altered pathway allowing resensitization of receptor signaling. This can greatly aid in the resolution of pathologies either initiated at the onset of leptin resistance or exacerbated by it.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner LINK THERAPEUTICS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap